Compositions and methods for treating chronic inflammation and inflammatory diseases

Patent metadata

Field	Value
Publication number	US-9750810-B2
Application number	US-201615043327-A
Country	US
Kind code	B2
Filing date	Feb 12, 2016
Priority date	Oct 29, 2010
Publication date	Sep 5, 2017
Grant date	Sep 5, 2017

Abstract

The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions.

First claim

The invention claimed is:

1. A pharmaceutical composition comprising:
a) about 10% to 30% of a propionic acid derivative NSAID by weight of the pharmaceutical composition;
b) about 5% to about 15% of a polyethylene glycol (PEG) polymer by weight of the pharmaceutical composition;
c) about 20% to about 50% of a hard fat comprising a triglyceride or a triester of glycerol by weight of the pharmaceutical composition; and
d) about 10% to about 30% of a liquid fat comprising a mono-glyceride by weight of the pharmaceutical composition,

wherein the pharmaceutical composition is formulated to be a solid at a temperature of about 15° C. or lower and have a melting point temperature in the range of about 25° C. or higher.

2. The pharmaceutical composition according to claim 1 , wherein the propionic acid derivative NSAID is about 20% to about 30% by weight of the pharmaceutical composition.

3. The pharmaceutical composition according to claim 2 , wherein the propionic acid derivative NSAID is in an amount from about 25% to about 30% by weight of the pharmaceutical composition.

4. The pharmaceutical composition according to claim 1 , wherein the propionic acid derivative NSAID comprises an Alminoprofen, a Benoxaprofen, a Dexketoprofen, a Fenoprofen, a Flurbiprofen, an Ibuprofen, an Indoprofen, a Ketoprofen, a Loxoprofen, a Naproxen, an Oxaprozin, a Pranoprofen, or a Suprofen.

5. The pharmaceutical composition according to claim 1 , wherein the propionic acid derivative NSAID is a pharmaceutically-acceptable form of an Ibuprofen.

6. The pharmaceutical composition according to claim 1 , wherein the hard fat or the triester of glycerol is in an amount from about 30% to about 50% by weight of the pharmaceutical composition.

7. The pharmaceutical composition according to claim 6 , wherein the hard fat or the triester of glycerol is in an amount from about 35% to about 45% by weight of the pharmaceutical composition.

8. The pharmaceutical composition according to claim 1 , wherein the hard fat or the triester of glycerol has a melting point of about 40° C. to about 46° C.

9. The pharmaceutical composition according to claim 8 , wherein the hard fat comprises a mixture of saturated C 10 -C 18 triglycerides having a melting point of between 41° C. to 45° C.

10. The pharmaceutical composition according to claim 9 , wherein the hard fat comprises a mixture of saturated C 10 -C 18 triglycerides having a melting point of about 43° C.

11. The pharmaceutical composition according to claim 1 , wherein the liquid fat is in an amount from about 15% to about 25% by weight of the pharmaceutical composition.

12. The pharmaceutical composition according to claim 1 , wherein the liquid fat further comprises a diglyceride, a triglyceride, or any combination thereof.

13. The pharmaceutical composition according to claim 1 , wherein the monoglyceride is glyceryl monolinoleate.

14. The pharmaceutical composition according to claim 1 , wherein the PEG polymer is in an amount from about 8% to about 15% by weight of the pharmaceutical composition.

15. The pharmaceutical composition according to claim 14 , wherein the PEG polymer is in an amount from about 7% to about 13% by weight of the pharmaceutical composition.

16. The pharmaceutical composition according to claim 15 , wherein the pharmaceutically-acceptable PEG polymer is in an amount from about 8% to about 12% by weight of the pharmaceutical composition.

17. The pharmaceutical composition according to claim 16 wherein the PEG polymer is in an amount from about 9% to about 11% by weight of the pharmaceutical composition.

18. The pharmaceutical composition according to claim 1 , wherein the PEG polymer is a liquid PEG polymer.

19. The pharmaceutical composition according to claim 18 , wherein the pharmaceutically-acceptable PEG polymer is less than about 2,000 g/mol.

20. The pharmaceutical composition according to claim 19 , wherein the liquid PEG polymer is a PEG 100, a PEG 200, a PEG 300, a PEG 400, a PEG 500, a PEG 600, a PEG 700, a PEG 800, a PEG 900, a PEG 1000, or a combination thereof.

Assignees

• Infirst Healthcare Ltd

Inventors

• Bannister Robin M
• Brew John
• Caparros-Wanderely Wilson
• Dilly Suzanne J
• Pleguezeulos Mateo Olga
• Stoloff Gregory A

Classifications

• A61K31/60

  Salicylic acid; Derivatives thereof · CPC title

• A61K9/08

  Solutions {(composition of solutions A61K47/00)} · CPC title

• A61K31/704

  attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)} · CPC title

• A61K31/337

  having four-membered rings, e.g. taxol · CPC title

• A61K31/25

  with polyoxyalkylated alcohols, e.g. esters of polyethylene glycol · CPC title